Medtronic to Buy CathWorks for $585M to Boost AI Cardiac Diagnostics

The transaction follows a 2022 strategic partnership and co-promotion agreement between the two companies. Medtronic confirmed that it has exercised its option to purchase the remaining shares of CathWorks for a total consideration of up to $585 million, plus potential undisclosed earn-out payments. The deal underscores a broader industry shift toward non-invasive, data-heavy diagnostic tools in cardiovascular medicine.

At the heart of the acquisition is the CathWorks FFRangio System, an artificial-intelligence-powered platform designed to assess coronary artery disease. Unlike traditional Fractional Flow Reserve (FFR) treatments that require invasive pressure wires and drug-induced stress, the CathWorks system uses routine angiograms to provide real-time data. Jason Weidman, head of Medtronic’s coronary and renal denervation business, stated that the technology allows the company to "transform the cath lab" by driving individualized treatment standards.

Financial Outlook and Integration

Medtronic expects the acquisition to close by the end of its fiscal 2026, subject to regulatory clearance from the Federal Trade Commission. Regarding its balance sheet, the company anticipates the deal will be immaterial to earnings in fiscal 2027, transitioning to a neutral-to-accretive impact in subsequent years.